0001193125-24-092036.txt : 20240410 0001193125-24-092036.hdr.sgml : 20240410 20240410171230 ACCESSION NUMBER: 0001193125-24-092036 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240405 ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CalciMedica, Inc. CENTRAL INDEX KEY: 0001534133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452120079 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39538 FILM NUMBER: 24836561 BUSINESS ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-952-5500 MAIL ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: CalciMedica, Inc. /DE/ DATE OF NAME CHANGE: 20230322 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG VISION, INC. DATE OF NAME CHANGE: 20170717 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG, Inc. DATE OF NAME CHANGE: 20150303 8-K 1 d690122d8k.htm 8-K 8-K
NASDAQ false 0001534133 0001534133 2024-04-05 2024-04-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 5, 2024

 

 

CalciMedica, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39538   45-2120079
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

505 Coast Boulevard South, Suite 307  
La Jolla, California   92037
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 952-5500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.0001 per share   CALC   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 4.01 Changes in Registrant’s Certifying Accountant.

(a) Dismissal of Independent Registered Public Accounting Firm

On April 5, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of CalciMedica, Inc. (the “Company”) approved the dismissal of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm. On April 5, 2024, EY was informed that they were dismissed.

EY’s audit reports on the Company’s financial statements for the years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

During the Company’s fiscal years ended December 31, 2023 and 2022, and the subsequent interim period through April 5, 2024: (1) there were no “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304) with EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused EY to make reference to the subject matter of such disagreements in connection with its reports on the financial statements for such periods and (2) there were no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K), except for the disclosure of the following material weakness in the Company’s internal control over financial reporting, as disclosed in Part I, Item 4 of the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, filed with the Securities and Exchange Commission (“SEC”) on May 12, 2023, August 11, 2023 and November 9, 2023, respectively: the Company did not design and maintain effective internal controls related to the accounting for the valuation of the Company’s convertible promissory notes and warrant liabilities.

The Company provided EY with a copy of this report prior to its filing with the SEC and requested that EY furnish the Company with a letter addressed to the SEC stating whether EY agrees with the statements made by the Company in this report and, if not, stating the respects, if any, in which EY does not agree with such statements. A copy of the letter from EY is filed with this Current Report on Form 8-K as Exhibit 16.1.

(b) Engagement of New Independent Registered Public Accounting Firm

On April 5, 2024, the Audit Committee approved the engagement of Moss Adams LLP (“Moss Adams”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. On April 9, 2024, Moss Adams was engaged as the Company’s independent registered public accounting firm.

During the Company’s fiscal years ended December 31, 2023 and 2022, and the subsequent interim period through April 9, 2024, neither the Company nor anyone acting on its behalf consulted with Moss Adams regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that Moss Adams concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a “disagreement” within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 or a “reportable event” within the meaning of Item 304(a)(1)(v) of Regulation S-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.		   

Description

16.1    Letter from Ernst & Young LLP to the SEC dated April 10, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      CalciMedica, Inc.
Date: April 10, 2024     By:  

/s/ A. Rachel Leheny, Ph. D.

   

Name:

Title:

  

A. Rachel Leheny, Ph. D.

Chief Executive Officer

 EX-16.1 2 d690122dex161.htm EX-16.1 EX-16.1

Exhibit 16.1

April 10, 2024

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Commissioners:

We have read Item 4.01 of Form 8-K dated April 10, 2024, of CalciMedica, Inc. and are in agreement with the statements contained in the second sentence of the first paragraph, and the second, third and fourth paragraphs on page 1 therein. We have no basis to agree or disagree with other statements of the registrant contained therein.

/s/ Ernst & Young LLP

EX-101.SCH 3 calc-20240405.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 calc-20240405_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 calc-20240405_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
Apr. 05, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001534133
Document Type 8-K
Document Period End Date Apr. 05, 2024
Entity Registrant Name CalciMedica, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39538
Entity Tax Identification Number 45-2120079
Entity Address, Address Line One 505 Coast Boulevard South
Entity Address, Address Line Two Suite 307
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (858)
Local Phone Number 952-5500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol CALC
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - d690122d8k.htm 7 calc-20240405.xsd calc-20240405_lab.xml calc-20240405_pre.xml d690122d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d690122d8k.htm": { "nsprefix": "calc", "nsuri": "http://www.calcimedica.com/20240405", "dts": { "schema": { "local": [ "calc-20240405.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "calc-20240405_lab.xml" ] }, "presentationLink": { "local": [ "calc-20240405_pre.xml" ] }, "inline": { "local": [ "d690122d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-04-05_to_2024-04-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d690122d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-04-05_to_2024-04-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d690122d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.calcimedica.com//20240405/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001193125-24-092036-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-092036-xbrl.zip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end XML 18 d690122d8k_htm.xml IDEA: XBRL DOCUMENT 0001534133 2024-04-05 2024-04-05 NASDAQ false 0001534133 8-K 2024-04-05 CalciMedica, Inc. DE 001-39538 45-2120079 505 Coast Boulevard South Suite 307 La Jolla CA 92037 (858) 952-5500 false false false false Common Stock, par value $0.0001 per share CALC true false